Duonco is a live biotherapeutic product targeting HER2 and CX3CR1, two breast cancer surface biomarkers. After association, the cell is engineered to produce outer membrane vesicles containing anticancer drugs. This evidence concerns the gene CX3CR1 and breast carcinoma.